Hepatitis B Drug Triggers HIV Drug Resistance

Finding calls for change in labeling and use, researchers say

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Abscess • Actinomycosis • Acute Myeloid Leukemia (Adult) • AIDS and HIV Infection More... Related Healthscout Videos Fighting HIV Heart Transplant Breakthrough Fighting a Killer Staph Infection Medical Debate: C-sections - Should You Choose? More... Related Animations • Erectile Dysfunction • Hepatitis • Menopause More... Related Drug Information • Abilify • Augmentin • Bactroban Cream • Bactroban Ointment More... Related News Articles • Health Tip: Before You Get Pregnant • Most Internet Sex Offenders Target Teens, Not Kids • Stimulating Thymus Reactivates T-Cell Production • FDA Panel OKs 3 New Flu Strains for Next Year's Vaccine More...

WEDNESDAY, Feb. 28 (HealthDay News) -- A commonly used hepatitis drug spurs resistance to HIV drugs in patients who are infected with both viruses, Johns Hopkins researchers report.

Although many medications have this problem, entecavir (Baraclude) was thought to be different.

Text Continues Below

---

"What that means is that [hepatitis B] patients, if they don't know they're HIV-positive, could start spreading drug-resistant HIV to other people," said Dr. Michael Horberg, director of HIV/AIDS policy at Kaiser Permanente Health Plan in Santa Clara, Calif. "And, once they are treated for HIV, it'll be harder to treat."

"We've always said that patients who are going to be treated for hepatitis B should be screened for HIV, even if they deny risk factors," Horberg added. "And, if they're co-infected, they probably should be treated for HIV as well, or at least be aware that they run the potential risk of creating a resistant virus."

However, Horberg did point out that the research comes from a tiny sample, only two patients. "Let's not draw conclusions based on only two patients, although it certainly is suggestive," he cautioned. "This small sample seems to lead to the question, 'Is it different?' "

The researchers, who are expected to present their findings Wednesday at the 2007 Conference on Retroviruses and Opportunistic Infections in Los Angeles, have already informed the U.S. Food and Drug Administration so prescribing physicians can be notified and drug labeling changed. They have also notified Baraclude's maker, Bristol-Myers Squibb.

"It gives you fewer choices in which to treat co-infected patients whose HIV doesn't need therapy yet," explained senior study author Dr. Chloe Thio, an associate professor of medicine at Johns Hopkins University School of Medicine. "The guidelines recommend entecavir as first-line therapy in HIV-infected patients who need their hepatitis B treated but not their HIV. That's no longer the case. With the data at present, the guidelines should be changed."

Page:  1 | 2 | Next >>